FOLH1 and posterior cortical atrophy: One patient (Patient 8, injected with a peptide mass of 80 μg) underwent SPECT visualization of PCa using the anti-PSMA targeting agent [99mTc]Tc-BQ0413 1 month before the current study (see Phase I study report [32], Patient 5).